Acutis Diagnostics INC

Acutis Diagnostics INC was paid $60.64M by Medicaid between Jan 2018 and Dec 2024, across 115 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 26% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#7 of 116

Median peer was paid$618K

This provider vs. median98×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	572,073	$6.06M
2019	436,824	$7.32M
2020	331,560	$10.90M
2021	455,668	$9.65M
2022	484,757	$9.85M
2023	340,437	$8.45M
2024incomplete	414,427	$8.40M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	26%	279,862	189,653	$15.60M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	13%	85,427	41,864	$7.69M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	12%	299,369	154,502	$7.49M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	9.3%	113,971	76,203	$5.64M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	6.4%	28,351	19,476	$3.87M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	4.8%	30,007	27,339	$2.94M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.7%	24,732	21,744	$2.25M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	3.3%	30,019	21,982	$2.01M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.1%	103,609	85,974	$1.30M
87631		<1%	20,156	19,326	$578K
83992		<1%	40,220	28,229	$475K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	21,616	20,752	$448K

103 more codes

80352		<1%	73,853	$433K
80333		<1%	47,311	$377K
80373		<1%	77,049	$359K
80370		<1%	46,708	$358K
80372		<1%	67,439	$344K
87481		<1%	23,238	$343K
80337		<1%	67,444	$340K
80371		<1%	64,866	$336K
80321		<1%	75,866	$318K
80368		<1%	64,616	$314K
80360		<1%	63,496	$304K
80357		<1%	65,243	$296K
80344		<1%	41,261	$291K
80323		<1%	78,103	$287K
80354		<1%	50,116	$275K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	22,342	$266K
80348		<1%	70,497	$266K
80355		<1%	62,260	$261K
80338		<1%	56,714	$261K
80366		<1%	54,940	$249K
80349		<1%	61,748	$242K
80324		<1%	55,092	$237K
80359		<1%	57,308	$228K
80346		<1%	54,358	$227K
80363		<1%	57,102	$221K
80365		<1%	56,047	$219K
80361		<1%	51,461	$216K
80358		<1%	51,387	$214K
87581		<1%	17,541	$214K
80353		<1%	48,846	$205K
80356		<1%	43,668	$192K
87640		<1%	22,415	$180K
87653		<1%	21,068	$172K
87486		<1%	12,666	$154K
80345		<1%	30,458	$139K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	9,054	$104K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	9,060	$101K
87632		<1%	3,623	$91K
80362		<1%	26,570	$88K
80364		<1%	20,871	$84K
87507		<1%	1,131	$74K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	2,084	$70K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	9,358	$70K
80369		<1%	8,764	$58K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	1,819	$41K
87563		<1%	5,359	$37K
80343		<1%	2,938	$32K
86769		<1%	1,098	$28K
81513		<1%	3,548	$27K
80332		<1%	4,140	$14K
87500		<1%	1,322	$13K
87181		<1%	6,102	$11K
80342		<1%	3,640	$8K
87071		<1%	1,768	$7K
86480		<1%	353	$6K
87634		<1%	467	$6K
81226		<1%	23	$4K
81003		<1%	5,995	$4K
87529		<1%	65	$4K
80335		<1%	950	$3K
81001		<1%	2,687	$3K
80334		<1%	2,146	$3K
81225		<1%	23	$3K
80350		<1%	764	$2K
80347		<1%	392	$2K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	365	$2K
80336		<1%	480	$2K
82570		<1%	1,194	$2K
81231		<1%	23	$2K
81401		<1%	23	$1K
80053	Comprehensive metabolic panel	<1%	447	$1K
83986		<1%	960	$1K
86706		<1%	248	$833.11
84315		<1%	857	$798.05
80061	Lipid panel	<1%	307	$656.45
82607		<1%	180	$644.86
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	349	$601.33
80074		<1%	102	$506.36
82746		<1%	132	$495.70
86803		<1%	117	$468.82
82043		<1%	336	$457.63
87506		<1%	28	$411.74
86704		<1%	106	$404.77
86708		<1%	107	$396.44
84403		<1%	30	$380.22
82150		<1%	142	$366.32
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	140	$328.20
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	58	$113.78
87081		<1%	110	$109.99
84270		<1%	28	$94.26
86780		<1%	56	$63.58
83036	Hemoglobin; glycosylated (A1C)	<1%	127	$44.66
84443	Thyroid stimulating hormone (TSH)	<1%	63	$33.60
85027		<1%	106	$19.41
84550		<1%	24	$6.09
83550		<1%	15	$3.93
86800		0%	13	$0.00
86376		0%	13	$0.00
36415	Collection of venous blood by venipuncture	0%	78	$0.00
99080		0%	198	$0.00
81479	Unlisted molecular pathology procedure	0%	23	$0.00
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	57	$0.00
87501		0%	124	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSARIJ, WAHID (GENERAL MANAGER)